- Home
- SEVN vs MXCT Comparison
SEVN vs MXCT Comparison
Compare SEVN & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- MXCT
- Stock Information
- Founded
- SEVN 1986
- MXCT 1999
- Country
- SEVN United States
- MXCT United States
- Employees
- SEVN N/A
- MXCT N/A
- Industry
- SEVN Real Estate Investment Trusts
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- SEVN Real Estate
- MXCT Health Care
- Exchange
- SEVN Nasdaq
- MXCT Nasdaq
- Market Cap
- SEVN 149.0M
- MXCT 159.9M
- IPO Year
- SEVN N/A
- MXCT 2021
- Fundamental
- Price
- SEVN $9.80
- MXCT $1.56
- Analyst Decision
- SEVN Strong Buy
- MXCT Buy
- Analyst Count
- SEVN 2
- MXCT 4
- Target Price
- SEVN $13.50
- MXCT $7.50
- AVG Volume (30 Days)
- SEVN 62.1K
- MXCT 577.9K
- Earning Date
- SEVN 10-27-2025
- MXCT 11-05-2025
- Dividend Yield
- SEVN 11.32%
- MXCT N/A
- EPS Growth
- SEVN N/A
- MXCT N/A
- EPS
- SEVN 1.04
- MXCT N/A
- Revenue
- SEVN $27,061,000.00
- MXCT $35,754,000.00
- Revenue This Year
- SEVN N/A
- MXCT N/A
- Revenue Next Year
- SEVN N/A
- MXCT $14.72
- P/E Ratio
- SEVN $9.53
- MXCT N/A
- Revenue Growth
- SEVN N/A
- MXCT N/A
- 52 Week Low
- SEVN $9.84
- MXCT $1.26
- 52 Week High
- SEVN $14.10
- MXCT $5.20
- Technical
- Relative Strength Index (RSI)
- SEVN 38.37
- MXCT 45.75
- Support Level
- SEVN $9.84
- MXCT $1.53
- Resistance Level
- SEVN $10.90
- MXCT $1.86
- Average True Range (ATR)
- SEVN 0.25
- MXCT 0.10
- MACD
- SEVN -0.02
- MXCT -0.02
- Stochastic Oscillator
- SEVN 8.49
- MXCT 10.14
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.